way-362450 and Dyslipidemias

way-362450 has been researched along with Dyslipidemias* in 1 studies

Other Studies

1 other study(ies) available for way-362450 and Dyslipidemias

Article	Year
Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes. Bioorganic & medicinal chemistry letters, 2011, Jan-01, Volume: 21, Issue:1 Herein we describe the synthesis and structure activity relationship of a new class of FXR agonists identified from a high-throughput screening campaign. Further optimization of the original hits led to molecules that were highly active in an LDL-receptor KO model for dyslipidemia. The most promising candidate is discussed in more detail. Topics: Administration, Oral; Animals; Binding Sites; Computer Simulation; Diabetes Mellitus, Experimental; Drug Evaluation, Preclinical; Dyslipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Mice; Mice, Knockout; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; Structure-Activity Relationship	2011

Article

Year

Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes.

Bioorganic & medicinal chemistry letters, 2011, Jan-01, Volume: 21, Issue:1

Herein we describe the synthesis and structure activity relationship of a new class of FXR agonists identified from a high-throughput screening campaign. Further optimization of the original hits led to molecules that were highly active in an LDL-receptor KO model for dyslipidemia. The most promising candidate is discussed in more detail.

Topics: Administration, Oral; Animals; Binding Sites; Computer Simulation; Diabetes Mellitus, Experimental; Drug Evaluation, Preclinical; Dyslipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Mice; Mice, Knockout; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; Structure-Activity Relationship

2011